ASBMT News  by unknown
BBMT IMPACT FACTOR
MOVES UP TO 3.278
Biology of Blood and Marrow
Transplantation has earned an ISI Im-
pact Factor of 3.278—its highest
since the journal was founded in
1995.
The ultimate measure of the suc-
cess of a medical journal is its actual
impact on research and clinical prac-
tice. However, in an effort to quantify
that impact, the Institute for Scientific
Information (ISI) computes and as-
signs a numeric “impact factor” to
peer-reviewed journals. The number
is based on the frequency of citations
of the journal’s articles in other scien-
tific publications in a given year.
The new impact factor places BBMT
in the following positions:
● 4th among 19 transplantation
journals
● 18th among 62 hematology jour-
nals
● 30th among 111 immunology
journals
“We are very pleased with the
progress of the journal and the way it
is being cited throughout the medical
literature,” said Dr. Nelson Chao,
ASBMT president. “I join with our of-
ficers and directors in congratulating
the editor-in-chief, Dr. Robert Korn-
gold, the associate editors, and the
members of the journal’s editorial
board.”
AUTHORS OF NIH-FUNDED
STUDIES MAY CHOOSE PUBMED
When authors submit manuscripts
on NIH-funded research to Biology of
Blood and Marrow Transplantation,
they will be asked whether they want
their published article forwarded to
the National Library of Medicine for
free public access on PubMed Cen-
tral.
If the author agrees, the article will
be forwarded to PubMed Central 12
months after appearing in the print
edition of the journal. The copyright
will continue to be maintained by the
journal and ASBMT.
The new ASBMT policy for its jour-
nal articles responds to NIH concerns
about free access to federally funded
research.
ABSTRACTS CAN BE SUBMITTED
FOR TANDEM MEETINGS IN HAWAII
Abstracts are being accepted for
the 2006 BMT Tandem Meetings,
Feb. 16-20 in Honolulu.
The abstract deadline is Oct. 3.
Meeting registration, housing reser-
vations, and abstract submission are
all online at the ASBMT Web site
www.asbmt.org.
TASK FORCE WILL STUDY
STEM CELL THERAPY OUTCOMES
An ASBMT ad hoc steering commit-
tee has been appointed to study the
feasibility of transplant center–specific
measures of quality in hematopoietic
stem cell therapy outcomes.
Chairing the steering committee is
Dr. Roy Jones of M. D. Anderson Can-
cer Center. Others include:
● Dr. John DiPersio, Washington
University Medical Center
● Dr. Helen Heslop, Baylor College
of Medicine (representing FACT)
● Dr. C. Fred LeMaistre, Texas Trans-
plant Institute (representing FACT)
● Dr. Samuel Silver, University of
Michigan Cancer Center
● Janet Sirilla, RN, Arthur G. James
Cancer Center Hospital (represent-
ing the BMT Center Administrative
Directors Special Interest Group)
● Dr. Claudio Anasetti, H. Lee Moffitt
Cancer Center & Research Institute
(ex-officio)
The ad hoc committee has evolved
from the BMT Center Medical Direc-
tors Conference held in February in
Keystone. A follow-up report on the
conference recommended the devel-
opment of methods to measure and
describe treatment outcomes for a
range of transplant facilities—large re-
search centers, community transplant
programs and specialized centers—
while keeping the administrative bur-
den of reporting to a minimum.
AABB PUBLISHES PHYSICIAN
CELLULAR THERAPY HANDBOOK
The AABB has published Cellular
Therapy: A Physician’s Handbook for
medical professionals, attending phy-
sicians, house officers, students,
nurses, technologists and other med-
ical personnel.
The handbook was developed in
cooperation with ASBMT, the Interna-
tional Society for Cellular Therapy and
the National Marrow Donor Pro-
gram. The editors are Drs. Edward
Snyder and Rebecca Haley.
For information and online orders,
visit the AABB Marketplace Web site
www.aabb.org.
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